中药概念集体高开，消息面上，2026年2月5日，工业和信息化部等八部门联合发布《中药工业高质量发 展实施方案（2026—2030年）》，本文件是对2025年3月《国务院办公厅 关于提升中药质量促进中医药 产业高质量发展的意见》的分解执行。文件部署了六方面任务：原料提质稳供、协同创新攻关、制造能 力提升、民族药产业振兴、卓越企业培育。到2030年，争取推动一批中药创新药获批上市，新培育10个 中成药大品种。分批次挖掘具有突出临床价值的中成药潜力品种，培育一批新的中成药大单品。依托中 国消费名品名单等载体，有序打造中药名品方阵 中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 数据显示，截至2026年1月30日，中证中药指数(930641)前十大权重股分别为云南白药、片仔癀、东阿 阿胶、同仁堂、吉林敖东、华润三九、白云山、以岭药业、众生药业、达仁堂，前十大权重股合计占比 55.13%。 中药ETF(159647)，场外联接(A：016891；C：016892；I：022881)。 机构认为：基药目录即将出台，院内中药大单品呼之欲 ...

Core Viewpoint - The Chinese traditional medicine sector is experiencing a significant boost due to favorable policies, leading to a strong market performance and increased trading volume in related ETFs and stocks [1][5]. Policy Developments - On February 5, eight departments jointly issued the "Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)," outlining goals and measures for the next five years to enhance the entire industry chain [5]. - The plan aims to establish a collaborative development system for the traditional Chinese medicine industry by 2030, focusing on stable supply of key raw materials, technological breakthroughs, and the cultivation of leading enterprises [5]. Market Performance - The leading traditional Chinese medicine ETF (560080) opened with a jump of over 2%, marking a strong upward trend with significant trading volume exceeding 160 million yuan within the first 20 minutes of trading [1]. - Notable stocks in the sector include Longshen Rongfa, Shanghai Kaibao, and Panlong Pharmaceutical, which saw increases of over 6%, while Hongri Pharmaceutical and Yiling Pharmaceutical rose by over 5% and 4%, respectively [2][3]. Investment Opportunities - Pacific Securities highlights the rapid growth of the traditional Chinese medicine market, driven by comprehensive policy support across various aspects, including registration, quality control, and cultural promotion [6]. - The sector is expected to benefit from a recovery in consumer demand, particularly due to aging demographics and increased health awareness, which will drive sales of consumer-oriented traditional Chinese medicine products [8]. Strategic Focus Areas - Three main investment themes are identified: 1. Price governance, focusing on companies with competitive advantages that can benefit from price reductions [8]. 2. Consumption recovery, driven by macroeconomic improvement and increased domestic demand [10]. 3. State-owned enterprise reform, which presents opportunities for performance improvement through efficiency gains [10]. Future Outlook - The traditional Chinese medicine industry is anticipated to undergo a reshuffling, with a focus on classic formulations and evidence-based medicine, positioning leading companies favorably for future growth [7].

Core Viewpoint - The "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" aims to establish a collaborative development system for the entire industry chain by 2030, enhancing the stable supply of key raw materials, improving digital and green transformation levels, achieving breakthroughs in key technologies, and significantly increasing collaborative innovation levels [3][14]. Group 1: Development Goals - The plan sets four main goals: improving development quality, enhancing collaborative systems, fostering innovative products, and achieving breakthroughs in digital and green transformation [4][15]. - Specific tasks include cultivating 60 high-standard raw material production bases and establishing five innovation centers for the traditional Chinese medicine industry [4][15]. - The plan aims to promote the approval of innovative traditional Chinese medicine drugs and develop 10 major new traditional Chinese medicine products [4][15]. Group 2: Specific Actions - The plan outlines 15 specific tasks focusing on actions such as improving raw material quality and supply, collaborative innovation, enhancing manufacturing capabilities, revitalizing the national medicine industry, promoting traditional Chinese medicine products, and nurturing outstanding enterprises [5][16]. - It emphasizes the establishment of high-standard raw material production bases and the development of intelligent circulation and storage management systems for traditional Chinese medicine materials [7][18]. Group 3: Innovation and Technology - The plan encourages the use of artificial intelligence and big data to enhance the research and development of traditional Chinese medicine, including the creation of knowledge graphs for classic formulas and experiences from renowned practitioners [9][20]. - It also supports the clinical trials of new traditional Chinese medicine drugs and aims to shorten the research and development cycle while reducing costs [9][20]. Group 4: Market and Brand Development - The plan includes initiatives to protect intellectual property rights for traditional brands and improve the production processes of existing traditional Chinese medicine products to enhance their clinical and market value [6][17]. - It encourages collaboration between traditional Chinese medicine enterprises and e-commerce platforms to provide efficient purchasing experiences for patients [6][17].

Core Viewpoint - The article discusses the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" issued by the Ministry of Industry and Information Technology and other departments, outlining goals for the development of the traditional Chinese medicine (TCM) industry over the next five years, focusing on supply stability, innovation, and digital transformation [1][3]. Group 1: Development Goals - The plan sets four major goals for the TCM industry by 2030, including the establishment of a collaborative development system, enhanced supply capabilities of key TCM raw materials, significant improvements in digital and green levels, and breakthroughs in key technologies [1][3]. - Specific tasks include improving the quality of TCM production, enhancing the collaborative system across the supply chain, and promoting the continuous emergence of innovative TCM products [3][5]. Group 2: Specific Actions - The plan outlines 15 specific tasks across six action areas, including actions to ensure stable supply of raw materials, promote collaborative innovation, enhance manufacturing capabilities, and revitalize the national medicine industry [5][9]. - For TCM raw materials, the plan emphasizes the construction of high-standard production bases and the establishment of a smart circulation and storage management system to ensure stable supply [7][9]. Group 3: Innovation and Product Development - The plan aims to foster the development of innovative TCM products, including the approval of new TCM drugs and the cultivation of major TCM varieties [3][5]. - It encourages collaboration between TCM enterprises and e-commerce platforms to enhance patient access to TCM products and improve the clinical and market value of TCM [5][9]. Group 4: Quality and Standards - The plan includes actions to enhance the quality standards of TCM, such as the formulation of national standards for TCM decoction pieces and the establishment of a quality traceability system [8][9]. - It also highlights the importance of protecting intellectual property rights for traditional brands and improving production processes for existing TCM products [5][9].

Core Viewpoint - The traditional Chinese medicine sector is experiencing active market performance, with several companies showing significant stock price increases amid broader market conditions [2] Company Performance - China Traditional Chinese Medicine (00570.HK) saw a stock price increase of 5.8%, reaching HKD 2.19 [2] - Yao Wang Tang (00897.HK) experienced a rise of 4.35%, with its stock priced at HKD 0.36 [2] - Tong Ren Tang Guo Yao (03613.HK) increased by 2.38%, trading at HKD 9.03 [2] - Tong Ren Tang Technology (01666.HK) rose by 1.83%, with a stock price of HKD 4.44 [2]

Report Summary 1. Report's Investment Rating for the Industry - No relevant investment rating information provided in the reports [1][2] 2. Core Views of the Report - The continuous improvement of the stock market since 2026 is due to factors such as the resonance of the technology cycle, the release of policy dividends, the economic recovery, and the return of overseas funds. In February, the market is expected to continue its phased positive trend, benefiting from the “Spring Market” window period, the release of policy dividends at the beginning of the “15th Five - Year Plan”, clear profit expectations for AI and overseas - expansion themes, seasonal recovery of the consumer end, and the implementation of investment projects. However, potential disturbances from overseas capital market fluctuations during the Spring Festival holiday, especially geopolitical risks, need to be watched out for [2] 3. Summary by Relevant Catalogs 3.1 Stock Index Futures Market - **IF Contracts**: The previous day's closing prices were 4671.60, 4665.20, 4636.00, and 4585.20 for the current month, next month, next quarter, and the quarter after next respectively. There were declines in price, with the largest decline of - 0.40 in the next - quarter contract. The trading volume was highest in the next - month contract (70168.00). Some contracts saw an increase in open interest, while the current - month contract decreased by 387.00 [1] - **IH Contracts**: The previous day's closing prices showed a decline. The largest decline in percentage was - 0.14 in the next - month contract. The trading volume was highest in the next - month contract (36122.00). All contracts had an increase in open interest, with the largest increase in the next - month contract (1146.00) [1] - **IC Contracts**: The previous day's closing prices decreased significantly. The largest decline in percentage was - 1.96 in the contract for the quarter after next. The trading volume was highest in the next - month contract (112281.00). All contracts had an increase in open interest, with the largest increase in the next - month contract (4345.00) [1] - **IM Contracts**: The previous day's closing prices decreased. The largest decline in percentage was - 1.67 in the contract for the quarter after next. The trading volume was highest in the next - month contract (142554.00). Some contracts had a decrease in open interest, such as the current - month contract which decreased by 3835.00 [1] - **Inter - monthly Spreads**: The current inter - monthly spreads for IF, IH, IC, and IM contracts were - 6.40, - 2.20, - 24.80, and - 38.00 respectively, showing changes compared to the previous values [1] 3.2 Stock Index Spot Market - **CSI 300 Index**: The previous day's index was 4698.68, with a trading volume of 264.88 billion lots and a total trading value of 6360.19 billion yuan, showing a 0.83% increase [1] - **SSE 50 Index**: The previous day's index was 3069.24, with a trading volume of 61.04 billion lots and a total trading value of 1698.82 billion yuan, showing a 1.14% increase [1] - **CSI 500 Index**: The previous day's index was 8068.08, with a trading volume of 275.82 billion lots and a total trading value of 4409.65 billion yuan, showing a - 1.69% decrease [1] - **CSI 1000 Index**: The previous day's index was 2520.32, with a trading volume of 4621.33 billion lots and a total trading value of 2642.27 billion yuan, showing a - 1.55% decrease [1] - **CSI 300 Industry Index**: Different industries had different performance. The main consumer, pharmaceutical and healthcare, and real estate and finance industries had positive growth rates of 2.73%, 1.19%, and 1.46% respectively, while the information technology industry had a - 1.89% decline [1] 3.3 Basis between Futures and Spot - **IF Contracts**: The basis between the current - month, next - month, and next - quarter IF contracts and the CSI 300 index was 0.12, - 5.08, and - 33.68 respectively [1] - **IC Contracts**: The basis between the IC contracts and the CSI 500 index showed significant negative values [1] - **IM Contracts**: The basis between the IM contracts and the CSI 1000 index also showed certain negative values [1] 3.4 Other Domestic and Overseas Indexes - **Domestic Indexes**: The Shanghai Composite Index, Shenzhen Component Index, and other domestic indexes showed different trends. For example, the Shanghai Composite Index had a 0.14% increase, while the Shenzhen Component Index had a - 0.88% decrease [1] - **Overseas Indexes**: The DAX index was 24373.06, with no information on its change compared to the previous period provided [1] 3.5 Macro Information - **Policy**: The Ministry of Finance, the General Administration of Customs, and the State Taxation Administration jointly announced tax exemptions for inbound goods purchased by Hainan Free Trade Port residents within the duty - free quota and product list, with an annual quota of 10,000 yuan per person and no limit on purchase frequency [2] - **Technology**: OpenAI launched GPT - 5.3 - Codex and a new enterprise - level platform Frontier, competing with Anthropic's Claude Opus 4.6 [2] - **Consumption and Trade**: The 2026 National Service Consumption and Service Trade Conference emphasized the shift from goods - consumption - led to service - consumption - led, and encouraged the cultivation of new service - consumption growth points and service exports. In 2025, China's service trade imports and exports reached 80823.1 billion yuan, a 7.4% increase year - on - year, with a reduction in the service trade deficit of 3439.5 billion yuan. Travel service imports and exports reached 22067 billion yuan, a 7.6% increase [2] - **International Relations**: The US established a critical minerals trade mechanism, with South Korea as the chair until June. China's Foreign Ministry opposed any country using “small - circle” rules to disrupt international economic and trade order [2] 3.6 Industry Information - **Photovoltaic Industry**: The China Photovoltaic Industry Association predicted that China's new photovoltaic installed capacity in 2026 would fall to 180GW - 240GW, and the average annual new installed capacity during the “15th Five - Year Plan” would be 238GW - 287GW. The Ministry of Industry and Information Technology emphasized addressing the industry's involution [2] - **Memory Industry**: The global HBM shortage has spread from data centers to the consumer electronics sector, especially affecting the smartphone industry. Qualcomm and Arm warned that the shortage would limit phone production, and some manufacturers planned to cut production and lower shipment targets [2] - **Traditional Chinese Medicine Industry**: Eight departments jointly issued a plan for the high - quality development of the traditional Chinese medicine industry, aiming to achieve certain goals by 2030, such as cultivating 60 high - standard raw material production bases [2] - **Internet Industry**: As of the end of 2025, China's netizen population reached 1.125 billion, with an Internet penetration rate exceeding 80%. The number of generative AI users reached 602 million, a 141.7% increase year - on - year, and the penetration rate was 42.8% [2]

消息面上，2月5日，工信部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》（以下简 称"实施方案"）。其中提到，到2030年，培育一批引领带动能力突出的中药工业领航企业，培育60个高 标准中药原料生产基地。推动一批中药创新药获批上市，新培育10个中成药大品种，推动一批医疗机构 中药制剂转化为中药创新药。 智通财经APP获悉，中医药概念逆市活跃，截至发稿，中国中药(00570)涨5.8%，报2.19港元；位元堂 (00897)涨4.35%，报0.36港元；同仁堂国药(03613)涨2.38%，报9.03港元；同仁堂科技(01666)涨1.83%， 报4.44港元。 光大证券表示，2026年中药行业的投资逻辑将从"成本修复"转向"价值成长"，政策红利的持续释放与企 业经营效率的提升，将推动行业盈利水平稳步改善。随着中医药"走出去"步伐加快，中药产品国际注册 与市场开拓的提速，具备品种优势与国际化能力的中药企业，有望在全球市场中获得新的增长空间。 ...

2月6日，A股三大指数集体低开，沪指下跌35.62点，跌幅0.87%报4040.30点，深成指下跌151.68点，跌 幅1.09%报13801.03点，创业板指下跌37.39点，跌幅1.15%报3222.88点，上证50下跌31.84点，跌幅 1.04%报3027.17点；A股中药（核心股）板块盘初走强，特一药业、盘龙药业双双涨停，生物谷涨超 16%，康缘药业、维康药业、陇神戎发、粤万年青等个股跟涨；退税商店板块连日走强；黄金概念（核 心股）股集体低开，湖南白银（核心股）、兴业银锡、盛达资源、白银有色跌停，豫光金铅跌超9%， 中国黄金、晓程科技等多股低开。 盘面上，市场焦点股横店影视（核心股）（6天5板）高开4.86%，并购重组的民爆光电（创业板4板） 低开1.95%、韩建河山（3板）竞价涨停、凯龙高科（创业板2板）竞价涨停，房地产（核心股）板块京 投发展（3板）平开，AI应用端的天地在线（14天7板）低开0.30%、遥望科技（4天2板）低开5.97%， 零售股茂业商业（5天3板）高开0.26%、杭州解百（2板）高开。 公司动态： 光模块放量、重大资产重组（核心股）与立案调查交织 新易盛：1.6T光模块进入持 ...

Market Overview - The gold and base metal sectors are experiencing a decline, while the semiconductor and computing hardware supply chains continue to drop [1] - The A-share market opened lower, with the Shanghai Composite Index down 0.87%, the Shenzhen Component Index down 1.09%, and the ChiNext Index down 1.15% [2][3] Sector Performance - The precious metals sector continues its downward trend, with companies like Hunan Silver, Xinyi Silver, and Shengda Resources hitting the daily limit down [1] - The Chinese medicine sector is active, with companies such as Te Yi Pharmaceutical and Panlong Pharmaceutical hitting the daily limit up, and Biotech Valley rising over 15% [1] - The oil and gas, chemical, and coal sectors are among the hardest hit, showing significant declines [3] Individual Stock Movements - Jiangfeng Electronics saw a slight increase of 0.09% after resuming trading, as the company plans to acquire control of Kaide Quartz [3] - The Hang Seng Index opened down 1.97%, with the Hang Seng Tech Index dropping 2.42%, and major tech stocks like Baidu and Alibaba falling over 3% [5][6]

A股开盘，三大指数集体低开，沪指跌0.87%报4040.3点，深证成指跌1.09%，创业板指跌1.15%。盘面 上，中药板块活跃，特一药业、盘龙药业涨停，工信部等八部门印发《中药工业高质量发展实施方案 （2026—2030年）》；金银、原油隔夜集体大跌，黄金、有色金属、油气板块低开。 ...